Kindeva Appoints Brok Weichbrodt As Chief Transformation Officer To Accelerate Growth Strategy And Commercial Excellence

Kindeva, a global drug delivery Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and accelerate growth as the company enters the next phase of its value creation plan.

With over 20 years of experience in the pharmaceutical and biotech sector, Brok has led large-scale transformation, built high-performing teams, and delivered complex operational programs. He previously played a key role in scaling Genezen from a start-up company into a best-in-class viral vector CDMO. Prior to Genezen, Brok led Drug Product Operations and Commercial Operations for Catalent Bloomington, successfully launching multiple commercial programs internationally. In this role, Brok will define and lead Kindeva’s transformation roadmap, aligning strategy with execution in supply chain, procurement, engineering, EHS, and ESG across all business units. He will ensure Kindeva continues to scale effectively in a highly regulated environment, while delivering consistent, high-quality outcomes for customers and patients.

“Joining Kindeva at such an exciting stage of its journey is a fantastic opportunity. I am looking forward to working with teams across the business to strengthen operational performance, accelerate strategic execution, and help position Kindeva for its next phase of sustainable growth,” commented Brok on the news. 

He continued, “With experience scaling clinical and commercial organizations through significant growth, I look forward to building on our strong foundations and working with our talented teams to deliver critical products for our customers and patients.” 

David Stevens, CEO at Kindeva, noted of the appointment, “Brok brings a proven track record of leading enterprise transformation and translating strategy into measurable results. His experience across operations, quality, and complex program delivery will be critical as we strengthen our global network, improve reliability, and scale the business. We are delighted to welcome him as we enter the next phase of growth.’

Find out more about Kindeva’s services here.

About Kindeva

Kindeva is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Manufacturing More Tomorrows™ for patients worldwide. We go beyond manufacturing to deliver strategic value through excellence in scalability and deep scientific expertise. Our comprehensive capabilities include Annex 1-aligned, state-of-the-art aseptic fill finish and next-generation sustainable inhalation propellant (NGP) technology. With proven expertise in pulmonary, nasal, dermal, and sterile injectable drug delivery, Kindeva partners with customers to meet today's demands while delivering the possibilities of tomorrow.